189 related articles for article (PubMed ID: 1498260)
1. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
[TBL] [Abstract][Full Text] [Related]
2. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
3. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
4. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
6. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
7. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products.
Gibson FM; Malkovska V; Myint AA; Meager A; Gordon-Smith EC
Exp Hematol; 1991 Aug; 19(7):659-63. PubMed ID: 1909968
[TBL] [Abstract][Full Text] [Related]
10. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
11. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
12. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.
Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G
Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999
[TBL] [Abstract][Full Text] [Related]
13. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points.
Verma UN; Mazumder A
Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308
[TBL] [Abstract][Full Text] [Related]
15. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
Chong AS; Scuderi P; Grimes WJ; Hersh EM
J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
[TBL] [Abstract][Full Text] [Related]
18. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
Reiter Z
Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
[TBL] [Abstract][Full Text] [Related]
20. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
